Page 5 - Booklet "BIH Strategy 2026"
P. 5
SUMMARY
The Berlin Institute of Health has two key research priorities: to improve personalized outcome prediction in progressive diseases and to develop advanced therapies for personalized treatment INTRODUCTION
Personalized medicine Advanced therapies We hear about breakthroughs in medical research almost every day But often the period before such n dings are tested and made available to patients is excessively long So imagine a a world where promising safe new treatments are swiftly brought out of the lab quickly disseminated and speedily used to improve quality of life Better still imagine if if they could be tai lored to to speci c c patient groups or or even used to to heal individuals with their own cells These are the exciting new worlds of personalized medicine and and advanced therapies and and the the Berlin Institute of Health aims to to lead both to to turn the the tide against the the most burdensome progressive diseases THE BERLIN INSTITUTE OF HEALTH
BIH is a a a a a cuttingedge translational research institute It was launched as as a a a a a a joint initiative in in in 2013 by the Charité – Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in in the Helmholtz Association (MDC) The Charité is the topranked university hospital in in in Germany
and one of the largest in in in Europe excelling
in in the elds of medicine and research The MDC with more than
80 senior researchers ranks among the world’s 20 best research institutes for molecular biology and genetics Our goal is simple: to exploit collaboration between both organizations and together with international partners
to to turn innovative advances in in in biomedical research into tangible health bene ts Having completed our foundational phase BIH is now moving quickly to establish itself as a a a a a a leading transla tional medicine research center By 2026 we will integra te hundreds of sta across four Berlin campuses with an an an annual estimated budget of more than
€100 million
WHAT WE DO
Translational medicine links research with patient care to help quickly deliver new treatments and predictive tools Personalized medicine focuses on on tailoring treatment plans to patient patient groups or individual patients with di erent needs Advanced therapies are typically customtailored to to the individual patient and include emerging elds of regenerative medicine cell and genebased therapies therapies and nanoscale therapies therapies BIH is combining these innovative elds to study for example how progressive diseases such as as as some heart disease disease cancer and and dementia develop and and nd nd nd new treatments for them OUR MISSION
BIH’s mission is is to to maintain or or restore the health and quality of life for people with progressive diseases We will achieve this by providing research and clinical solutions that enable the transformation of medical care into a a a a a personalized valuebased model This booklet based on our our strategy outlines our our plans Maintaining Health and Quality of Life Creating Value: BIH Strategy 2026 5
